Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...

B.Riley Financial analyst William Wood has reiterated their bullish stance on IMUX stock, giving a Buy rating on September 16. William Wood ...

Tolebrutinib belongs to a class of drugs that target microglia through an enzymatic ... Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical ...

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...